Vertex Pharmaceuticals Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Vertex Pharmaceuticals Inc Stock Forecast and Price Target
The average target price for Vertex Pharmaceuticals Inc's stock set by eleven renowned analysts in recent months is $450.00, representing a potential upside of approximately 14.13% from its last closing price if met by 2025. This estimation is based on a high estimate of $574.00 and a low estimate of $325.00. Even if you are not interested in VRTX stock, it is still imperative to be aware of its competitors.
14.13% Upside
Vertex Pharmaceuticals Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Vertex Pharmaceuticals Inc's Price has decreased from $271.21 to $0.00 – a 100.00% drop! In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $423.63 – an increase of 100.00%. Over the next seven years, experts anticipate that Fair Value growth for Vertex Pharmaceuticals Inc will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$726.31 | Buy/Sell | $636.99 | 15.31% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$147.91 | Buy/Sell | $174.55 | 14.93% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$125.78 | Buy/Sell | $130.51 | 10.91% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$26.00 | Buy/Sell | $32.87 | 17.31% |
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.93 | Buy/Sell | $58.15 | 12.41% |
Vertex Pharmaceuticals Inc Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Revenue for Vertex Pharmaceuticals Inc has grown by 59.03%, going from $6.21B to $9.87B. The next year, 17 experts forecast that Vertex Pharmaceuticals Inc's Revenue will decrease by 1.50%, reaching $9.72B. Over the next seven years, experts anticipate that Revenue growth for Vertex Pharmaceuticals Inc will be 30.19%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$896.82 | Buy/Sell | $961.26 | 17.08% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$146.50 | Buy/Sell | $220.47 | 51.19% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$39.47 | Buy/Sell | $44.86 | 14.01% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$144.41 | Buy/Sell | $245.24 | 48.88% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.25 | Buy/Sell | $11.73 | 6.67% |
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$237.93 | Buy/Sell | $284.08 | 24.83% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Hold |
15
|
$55.48 | Buy/Sell | $49.29 | 14.46% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$67.55 | Buy/Sell | $87.92 | 39.16% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$40.68 | Buy/Sell | $55.60 | 47.98% |
Vertex Pharmaceuticals Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Vertex Pharmaceuticals Inc's EBITDA has grown, increasing from $2.98B to $4.48B – an increase of 50.29%. For next year, the 1 analysts predict EBITDA of $5.94B, which would mean an increase of 32.63%. Over the next seven years, the pros' prediction is EBITDAof $11.25B, which would mean a seven-year growth forecast of 151.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$212.04 | Buy/Sell | $315.92 | 83.93% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$143.48 | Buy/Sell | $145.00 | 13.60% |
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$30.80 | Buy/Sell | $44.75 | 29.87% |
Vertex Pharmaceuticals Inc EBIT Forecast for 2023 - 2025 - 2030
Vertex Pharmaceuticals Inc's EBIT has increased by 50.12% In the last three years, going from $2.87B to $4.31B. In the next year, analysts expect EBIT to reach $5.18B – an increase of 20.31%. For the next seven years, the forecast is for EBIT to grow by 69.60%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$11.61 | Buy/Sell | $37.00 | 46.43% |
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$40.01 | Buy/Sell | $69.00 | 54.96% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$13.78 | Buy/Sell | $29.44 | 146.73% |
Vertex Pharmaceuticals Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Vertex Pharmaceuticals Inc's EPS has decreased from $10.32 to $0.00 – a 100.00% drop! In the coming year, analysts are expecting an increase in EPS, predicting it will reach $16.12 – an increase of 100.00%. Over the next seven years, experts anticipate that EPS growth for Vertex Pharmaceuticals Inc will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$22.95 | Buy/Sell | $35.67 | 65.58% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£15.14 | Buy/Sell | £28.89 | 108.06% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$7.92 | Buy/Sell | $17.83 | 120.96% |
Site Navigation
.jpg)